Citigroup Issues Pessimistic Forecast for Bruker (NASDAQ:BRKR) Stock Price

Bruker (NASDAQ:BRKR - Free Report) had its target price reduced by Citigroup from $75.00 to $50.00 in a report released on Monday morning,Benzinga reports. Citigroup currently has a buy rating on the medical research company's stock.

A number of other research analysts have also recently commented on the company. Guggenheim restated a "buy" rating on shares of Bruker in a research note on Monday, February 24th. UBS Group began coverage on shares of Bruker in a report on Tuesday, December 10th. They set a "neutral" rating and a $66.00 target price on the stock. Barclays decreased their price target on shares of Bruker from $69.00 to $65.00 and set an "overweight" rating for the company in a research note on Monday, February 10th. Bank of America lifted their price target on shares of Bruker from $78.00 to $80.00 and gave the company a "buy" rating in a research report on Friday, December 13th. Finally, Stifel Nicolaus cut their price objective on shares of Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a report on Friday, February 14th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $66.50.

Bruker Trading Up 1.8 %

NASDAQ:BRKR traded up $0.69 during trading hours on Monday, hitting $38.76. The company had a trading volume of 3,139,890 shares, compared to its average volume of 1,467,987. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77. The stock has a 50-day moving average price of $46.16 and a 200 day moving average price of $54.75. The company has a market capitalization of $5.88 billion, a PE ratio of 51.00, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. Bruker has a 52 week low of $34.10 and a 52 week high of $90.03.

Remove Ads

Bruker (NASDAQ:BRKR - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, beating analysts' consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. On average, equities research analysts predict that Bruker will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Monday, March 17th were paid a dividend of $0.05 per share. The ex-dividend date was Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a yield of 0.52%. Bruker's dividend payout ratio is presently 26.32%.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in BRKR. Wealth Enhancement Advisory Services LLC raised its position in shares of Bruker by 1.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 13,287 shares of the medical research company's stock valued at $779,000 after buying an additional 177 shares during the last quarter. Quadrant Capital Group LLC boosted its stake in shares of Bruker by 18.2% during the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock worth $75,000 after purchasing an additional 196 shares during the period. Insigneo Advisory Services LLC grew its stake in shares of Bruker by 4.7% during the fourth quarter. Insigneo Advisory Services LLC now owns 4,880 shares of the medical research company's stock valued at $286,000 after buying an additional 218 shares during the last quarter. Arizona State Retirement System grew its position in Bruker by 0.7% in the 4th quarter. Arizona State Retirement System now owns 30,725 shares of the medical research company's stock valued at $1,801,000 after acquiring an additional 222 shares during the last quarter. Finally, CIBC Asset Management Inc grew its holdings in shares of Bruker by 5.6% in the fourth quarter. CIBC Asset Management Inc now owns 4,233 shares of the medical research company's stock worth $248,000 after purchasing an additional 223 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.